תבנית:תרופה/אקסטביה - Extavia: הבדלים בין גרסאות

|התוויה={{{התוויה|<div style="direction:ltr;">Extavia is indicated for the treatment of:• For use in relapsing-remitting and relapsing-progressive multiple sclerosis. It is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite MS, and who have experienced at least two exacerbations over the last two years.Extavia reduces the frequency of clinical exacerbations.In secondary progressive multiple sclerosis Extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. Compared with placebo, patients receiving Extavia showed a statistically significant delay in time to progression of multiple sclerosis. The treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). Patients receiving Extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. See also Section 5.1 “Pharmacodynamic properties”. Secondary progressive multiple sclerosis patients receiving Extavia showed a reduction in frequency (30%) of clinical relapses. There is no evidence of an effect of Extavia on the duration of exacerbations.</div>}}}

|התוויה={{{התוויה|<div style="direction:ltr;">Extavia is indicated for the treatment of:• For use in relapsing-remitting and relapsing-progressive multiple sclerosis. It is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite MS, and who have experienced at least two exacerbations over the last two years.Extavia reduces the frequency of clinical exacerbations.In secondary progressive multiple sclerosis Extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. Compared with placebo, patients receiving Extavia showed a statistically significant delay in time to progression of multiple sclerosis. The treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). Patients receiving Extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. See also Section 5.1 “Pharmacodynamic properties”. Secondary progressive multiple sclerosis patients receiving Extavia showed a reduction in frequency (30%) of clinical relapses. There is no evidence of an effect of Extavia on the duration of exacerbations.</div>}}}

|שם יצרן={{{שם יצרן|[[יצרן::BAYER PHARMA AG, GERMANY]]}}}

|שם יצרן={{{שם יצרן|[[יצרן::BAYER PHARMA AG, GERMANY]]}}}

|שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::NOVARTIS PHARMA SERVICES AG]]}}}

|שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::NOVARTIS PHARMA SERVICES AG]]}}}

|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::07/2011]]}}}

|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::07/2011]]}}}

|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Extavia|אקסטביה}}}}}

|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Extavia|אקסטביה}}}}}

|עלון לרופא={{{עלון לרופא|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Extavia_dr_1326866226277.pdf עלון לרופא]}}}

|עלון לרופא={{{עלון לרופא|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Extavia_dr_1326866226277.pdf עלון לרופא]}}}

|החמרות לעלון={{{החמרות לעלון|}}}

|החמרות לעלון={{{החמרות לעלון|}}}

|מספר רישום={{{מספר רישום|146 44 33127 00}}}

|מספר רישום={{{מספר רישום|146 44 33127 00}}}

|תמונת אריזה={{{תמונת אריזה|}}}

|תמונת אריזה={{{תמונת אריזה|}}}

|שיווק הופסק={{{שיווק הופסק|לא}}}

|שיווק הופסק={{{שיווק הופסק|לא}}}

|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}

|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}

}}

}}

<noinclude>{{תרופה/תיעוד}}</noinclude>

<noinclude>{{תרופה/תיעוד}}</noinclude>